This comprehensive analysis examines the clinical differences between typical and atypical antipsychotic medications in treating mental disorders. The paper evaluates treatment protocols for psychosis, focusing on risperidone as a first-line therapy option and discussing transition strategies to lithium therapy. Key considerations include side effect monitoring, patient safety protocols, and long-term treatment management approaches.
First-generation antipsychotics (FGAs), also called typical anti-psychotics, and second-generation antipsychotics (SGAs), known as atypical anti-psychotics, differ significantly in their mechanisms and side effect profiles. FGAs primarily block dopamine D2 receptors in the central nervous system (CNS) (Leucht et al., 2021). This strong dopamine blockade effectively reduces positive psychotic symptoms like hallucinations and delusions but often results in extrapyramidal symptoms (EPS), such as dystonia, parkinsonism, akathisia, and tardive dyskinesia. These side effects can be debilitating and limit long-term use.
In contrast, SGAs block both dopamine D2 receptors and serotonin 5-HT2 receptors (Leucht et al., 2021). This dual mechanism reduces the likelihood of EPS, making SGAs more tolerable for many patients. However, SGAs carry a higher risk of metabolic side effects, including diabetes, weight gain, and dyslipidemia, which could increase the risk of cardiovascular disease (Fabrazzo et al., 2022). Despite these risks, SGAs are generally favored due to their broader efficacy, including improvements in both positive and negative indications of psychosis, as well as cognitive function? (Rosenthal & Burchum, 2020, p. 203).
For KN, a 26-year-old male newly diagnosed with psychosis and without comorbidities, risperidone is a suitable first-line treatment. Risperidone is an SGA with proven efficacy in managing both positive indications, such as hallucinations and delusions, and negative symptoms, including social withdrawal and lack of motivation (Rosenthal & Burchum, 2020, p. 211). Though not without concerns, its side effect profile is manageable with appropriate monitoring.
Alternatively, olanzapine may be considered for its strong efficacy in symptom control. However, it carries a higher risk of significant weight gain and metabolic disturbances, essential considerations for young patients who may be more affected by these changes. Both drugs have the advantage of lower EPS risks compared to FGAs, which is a critical factor for preserving the quality of life in younger, active individuals. Treatment choice should be individualized based on patient preference, tolerability, and emerging side effects?.
For risperidone, monitoring involves assessing both therapeutic outcomes and potential adverse effects. Efficacy should be measured by the reduction of psychotic symptoms, including hallucinations, delusions, and agitation, as well as improvements in daily functioning and cognitive processes.
Regarding side effects, routine checks of weight, blood glucose levels, and lipid profiles are essential due to the risk of metabolic syndrome (Rosenthal & Burchum, 2020, p. 211). Early identification of sedation, orthostatic hypotension, and rare but serious adverse effects like neuroleptic malignant syndrome (NMS) is also critical. Baseline metabolic assessments should be conducted before initiating treatment and periodically during therapy, including body mass index (BMI), fasting blood glucose, and lipid panels. Regular evaluation of the patient’s adherence and response to therapy will guide dosage adjustments and ensure long-term treatment success?.
If a decision is made to transition to lithium after two years of inadequate response to anti-psychotics, careful monitoring is vital. Lithium is effective for mood stabilization in conditions like bipolar disorder and can augment the treatment of psychosis in specific cases. However, it carries substantial risks of side effects and toxicity (Rosenthal & Burchum, 2020, p. 228).
Common side effects include tremors, increased thirst (polydipsia), increased urination (polyuria), weight gain, and gastrointestinal symptoms such as nausea and diarrhea. Long-term use can lead to hypothyroidism and renal impairment, necessitating periodic monitoring of thyroid function and renal parameters. Lithium has a narrow therapeutic index, with serum levels ideally maintained between 0.6 and 1.2 mEq/L. Toxicity, characterized by symptoms like confusion, ataxia, severe nausea, or seizures, can occur with serum levels above this range and requires immediate intervention (Rosenthal & Burchum, 2020, p. 231).
Baseline and regular monitoring of serum lithium levels, renal function tests (e.g., creatinine, blood urea nitrogen), and thyroid function tests are mandatory. Patients should also be educated on maintaining consistent hydration and avoiding medications like nonsteroidal anti-inflammatory drugs (NSAIDs), which can increase lithium levels. Regular follow-ups are essential to adjust dosages and prevent complications?.
You’re 80% through this paper. Sign up to read the full paper.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.